卡介菌多糖核酸结合NB-UVB治疗特应性皮炎疗效分析OA

Objective To explore the efficacy of BCG-polysaccharide nucleic acid combined with narrow band ultraviolet B(NB-UVB)in the treatment of atopic dermatitis.Methods A total of 96 patients with atopic dermatitis were enrolled between January 2024 and June 2025.They were randomly divided into Control Group 1(32 cases,intramuscular injection of BCG-polysaccharide nucleic acid),Control Group 2(32 cases,NB-UVB treatment)and Observation Group(32 cases,intramuscular injection of BCG-polysaccharide nucleic acid combined with NB-UVB treatment)using a simple randomization method.All patients were treated continuously for 1 month.The clinical efficacy,symptom evaluation,skin barrier function,serum inflammatory factors and adverse reactions were compared among the three groups.Results The total response rate of treatment in Observation Group was 90.62%(29/32),higher than that in Control 1 Group and Control 2 Group[62.50%(20/32),68.75%(22/32),P<0.05].After treatment,the scores of Scoring Atopic Dermatitis(SCORAD)and Peak Pruritus Numerical Rating Scale(PP-NRS),transdermal water loss and serum levels of interleukins(IL-13,IL-31 and IL-22)were decreased,while the stratum corneum water content and sebum content were increased in all three groups,and all the above indicators in the Observation Group were superior to those in Control Group 1 and Control Group 2(P<0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion The efficacy of BCG-polysaccharide nucleic acid combined with NB-UVB is significantly superior than that of single treatment in the treatment of patients with atopic dermatitis,which can effectively alleviate symptoms,significantly repair skin barrier function and down-regulate levels of inflammatory factors,with good safety.